Form 483

PD-Rx Pharmaceuticals Inc. Form 483, 2022-11-10

FDA issued a Form 483 to PD-Rx Pharmaceuticals Inc. on 2022-11-10 with 5 public-safe observations.

483· Form 483 issuedHuman Drugs5 observations

PD-Rx Pharmaceuticals Inc. · Oklahoma City, United States · Issued November 10, 2022

Overview

  • 5 public-safe observations are available for this inspection.
  • 4 structured CFR citations are represented.
  • 3 investigators are tied to this Form 483.

Inspectional observations

Each observation cites the regulation FDA found the firm out of compliance with.

10 Nov 2022
21 CFR 211.100(a)

Absence of Written Procedures

Cited by Margaret M Annes, Dorothy P Kramer, Christopher N Tran

10 Nov 2022
21 CFR 211.100(a)

Changes to Procedures Not Reviewed, Approved

Cited by Margaret M Annes, Dorothy P Kramer, Christopher N Tran

10 Nov 2022
21 CFR 211.22(d)

Procedures not in writing, fully followed

Cited by Margaret M Annes, Dorothy P Kramer, Christopher N Tran

10 Nov 2022
21 CFR 211.25(a)

Training , Education , Experience overall

Cited by Margaret M Annes, Dorothy P Kramer, Christopher N Tran

10 Nov 2022
21 CFR 211.67(b)

Written procedures not established/followed

Cited by Margaret M Annes, Dorothy P Kramer, Christopher N Tran

Inspected site

PPPD-Rx Pharmaceuticals Inc.Oklahoma City, United States

Inspection team

CNChristopher N Tran

Cited regulations

CFR citations associated with this Form 483.

CitationWhat it coversCited
21 CFR 211.100(a)Cited across public-safe Form 483 observations2x
21 CFR 211.22(d)Cited across public-safe Form 483 observations1x
21 CFR 211.25(a)Cited across public-safe Form 483 observations1x
21 CFR 211.67(b)Cited across public-safe Form 483 observations1x

Source document

PDF
PDF available

Form 483 source document

The source document is available to authorized Atlas users.

Full 483 report

Get the verbatim text of all 5 observations

The source PDF, so your team sees exactly what was cited and how it was answered.

  • The site's full inspection history around this Form 483
  • Whether these citations escalated to a warning letter
  • The investigators involved and the citations they repeat elsewhere